Haleon's dual-placement strategy for Advil and TUMS at CVS lifted first-quarter sales per store, and talks with Walmart are ...

President Donald Trump said his administration is pressuring pharmaceutical companies to break up childhood vaccines into ...

Arif on Media' can be read here. Click here to read Arif's most recent stories for Media Week and Campaign. Mark Frith is making a return to magazines as editor-in-chief of Now, Time Inc's celebrity ...

FDA approved KERENDIA (finerenone) as the first new treatment in 30 years for adults with chronic kidney disease associated ...

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

Tempus AI (TEM) stock surged 15% Thursday as CEO outlined up to $400M in Medicare revenue. TEM is up 92% from its July low.

Tempus AI (TEM) stock jumped 15% Thursday after CEO outlined Medicare revenue expectations up to $400M. Shares have surged 92% since July bottom.

Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate ...

GSK slides 1.82% today to GBX1865.50 despite ongoing progress in oncology and vaccines, with volatility remaining elevated.

GSK (LSE: GSK) has delivered a 58.4% share price return over the past five years, putting real pressure on the question of whether current earnings justify ...

The life sciences industry is entering a period in which artificial intelligence is increasingly becoming part of how ...